Bexarotene is an anticancer agent developed by Ligand Pharmaceuticals and marketed under the trade name Targretin. It was approved by the FDA for treating cutaneous T-cell lymphoma in 1999. The rights to bexarotene were purchased by Eisai in 2006. Recently, G. Landreth and co-workers showed that bexarotene removes amyloid-β protein from the brains of mice with Alzheimer’s disease (AD) and thus restores their memory. Whether this finding can be applied to AD in humans remains to be seen.
Learn more about this molecule from CAS, the most authoritative and comprehensive source for chemical information.